GLP-1 receptor agonists have revolutionized the treatment of diabetes and obesity, but recent data suggest a potential link to a higher risk of various ocular disorders, especially with long-term use. This episode reviews the findings of these studies, places them in context with the overall benefits of GLP-1s, and covers what pharmacists should know when counseling patients. Listen in to enhance your ability to guide safe, informed medication choices and stay updated on emerging safety information.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Jamie Pitlick, PharmD, BCPS, BC-ADM
Professor and Chair of Pharmacy Practice
Drake University College of Pharmacy and Health Sciences

Joshua Davis Kinsey and Jamie Pitlick have no relevant financial relationships with ineligible companies to disclose.
 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the potential relationship between GLP-1 receptor agonist use and the development of ocular disorders.
2. Identify key considerations for pharmacist counseling related to GLP-1 therapy and ocular health.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-311-H01-P
Initial release date: 10/27/2025
Expiration date: 10/27/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram